Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1994 1
1995 1
1996 2
1997 1
1998 3
1999 3
2000 1
2001 3
2003 1
2004 2
2006 1
2007 4
2008 8
2009 7
2010 8
2011 4
2012 5
2013 10
2014 8
2015 10
2016 7
2017 6
2018 8
2019 11
2020 12
2021 4
2022 14
2023 4
2024 7
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Montano-Loza AJ, Ebadi M, Mason AL. Montano-Loza AJ, et al. Among authors: mason al. Gastroenterology. 2019 Jun;156(8):2354-2355. doi: 10.1053/j.gastro.2019.04.039. Epub 2019 Apr 27. Gastroenterology. 2019. PMID: 31039341 No abstract available.
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ. Harms MH, et al. Among authors: mason al. J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11. J Hepatol. 2019. PMID: 30980847
COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.
Kowdley KV, Hirschfield GM, Coombs C, Malecha ES, Bessonova L, Li J, Rathnayaka N, Mells G, Jones DE, Trivedi PJ, Hansen BE, Smith R, Wason J, Hiu S, Kareithi DN, Mason AL, Bowlus CL, Muller K, Carbone M, Berenguer M, Milkiewicz P, Adekunle F, Villamil A. Kowdley KV, et al. Among authors: mason al. Am J Gastroenterol. 2025 Feb 1;120(2):390-400. doi: 10.14309/ajg.0000000000003029. Epub 2024 Aug 14. Am J Gastroenterol. 2025. PMID: 39140490 Free PMC article. Clinical Trial.
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.
Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Murillo Perez CF, et al. Among authors: mason al. Am J Gastroenterol. 2020 Jul;115(7):1066-1074. doi: 10.14309/ajg.0000000000000557. Am J Gastroenterol. 2020. PMID: 32618657
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Corpechot C, Mayo MJ, Battezzati PM, Parés A, Nevens F, Burroughs AK, Kowdley KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE; Global PBC Study Group. Lammers WJ, et al. Among authors: mason al. Gastroenterology. 2014 Dec;147(6):1338-49.e5; quiz e15. doi: 10.1053/j.gastro.2014.08.029. Epub 2014 Aug 23. Gastroenterology. 2014. PMID: 25160979
Development of a Question Prompt List for People Living With Primary Biliary Cholangitis: A Delphi Study.
Werner E, van Hooff MCB, Weijsters GHX, Abbas N, Gerussi A, Willemse JA, Mitchell-Thain R, Leburgue A, Hirschfield GM, Corpechot C, Schramm C, Levy C, Nevens F, Verbeek J, Mason AL, Dalekos G, Cazzagon N, Mells GF, Kowdley KV, Carbone M, Jones DE, Hansen BE, Trivedi PJ, van der Meer AJ; Global PBC Study Group/ERN RARE-LIVER/Question Prompt List. Werner E, et al. Among authors: mason al. Clin Gastroenterol Hepatol. 2025 Oct;23(11):1935-1942.e5. doi: 10.1016/j.cgh.2025.01.037. Epub 2025 Apr 15. Clin Gastroenterol Hepatol. 2025. PMID: 40246040 Free article.
De novo and recurrent liver disease.
Ip S, Bhanji RA, Ebadi M, Mason AL, Montano-Loza AJ. Ip S, et al. Among authors: mason al. Best Pract Res Clin Gastroenterol. 2020 Jun-Aug;46-47:101688. doi: 10.1016/j.bpg.2020.101688. Epub 2020 Sep 23. Best Pract Res Clin Gastroenterol. 2020. PMID: 33158472 Review.
Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.
Montano-Loza AJ, Ronca V, Ebadi M, Hansen BE, Hirschfield G, Elwir S, Alsaed M, Milkiewicz P, Janik MK, Marschall HU, Burza MA, Efe C, Calışkan AR, Harputluoglu M, Kabaçam G, Terrabuio D, de Quadros Onofrio F, Selzner N, Bonder A, Parés A, Llovet L, Akyıldız M, Arikan C, Manns MP, Taubert R, Weber AL, Schiano TD, Haydel B, Czubkowski P, Socha P, Ołdak N, Akamatsu N, Tanaka A, Levy C, Martin EF, Goel A, Sedki M, Jankowska I, Ikegami T, Rodriguez M, Sterneck M, Weiler-Normann C, Schramm C, Donato MF, Lohse A, Andrade RJ, Patwardhan VR, van Hoek B, Biewenga M, Kremer AE, Ueda Y, Deneau M, Pedersen M, Mayo MJ, Floreani A, Burra P, Secchi MF, Beretta-Piccoli BT, Sciveres M, Maggiore G, Jafri SM, Debray D, Girard M, Lacaille F, Lytvyak E, Mason AL, Heneghan M, Oo YH; International Autoimmune Hepatitis Group (IAIHG). Montano-Loza AJ, et al. Among authors: mason al. J Hepatol. 2022 Jul;77(1):84-97. doi: 10.1016/j.jhep.2022.01.022. Epub 2022 Feb 8. J Hepatol. 2022. PMID: 35143897 Free article.
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.
Roberts SB, Choi WJ, Worobetz L, Vincent C, Flemming JA, Cheung A, Qumosani K, Swain M, Grbic D, Ko HH, Peltekian KM, Abrahamyan L, Saini M, Tirona K, Aziz B, Lytvyak E, Invernizzi P, Ponsioen CY, Bruns T, Cazzagon N, Lindor K, Dalekos GN, Gatselis NK, Verhelst X, Floreani A, Corpechot C, Mayo MJ, Levy C, Londoño MC, Battezzati PM, Pares A, Nevens F, van der Meer A, Kowdley KV, Trivedi PJ, Lleo A, Thorburn D, Carbone M, Selzner N, Gulamhusein AF, Janssen H, Montano-Loza AJ, Mason AL, Hirschfield GM, Hansen BE; Canadian Network for Autoimmune Liver disease (CaNAL). Roberts SB, et al. Among authors: mason al. JHEP Rep. 2024 Jul 8;6(10):101168. doi: 10.1016/j.jhepr.2024.101168. eCollection 2024 Oct. JHEP Rep. 2024. PMID: 39380718 Free PMC article.
142 results